185 related articles for article (PubMed ID: 34326735)
1. Chronic Myeloid Leukemia in a Patient with Hepatitis B Virus Infection: A Case Report.
Ali Hailan YM; Mudawi D; Yassin MA
Case Rep Oncol; 2021; 14(2):1004-1009. PubMed ID: 34326735
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.
Atteya A; Ahmad A; Daghstani D; Mushtaq K; Yassin MA
Cancer Control; 2020; 27(1):1073274820976594. PubMed ID: 33297765
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
McCormack PL; Keam SJ
BioDrugs; 2012 Feb; 26(1):61-4. PubMed ID: 22233429
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
McCormack PL; Keam SJ
Drugs; 2011 Sep; 71(13):1771-95. PubMed ID: 21902298
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
6. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
7. Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.
Baran Y; Saydam G
J Blood Med; 2012; 3():139-50. PubMed ID: 23180974
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Jabbour E; Kantarjian H
Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
[TBL] [Abstract][Full Text] [Related]
9. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
Ikeda K; Shiga Y; Takahashi A; Kai T; Kimura H; Takeyama K; Noji H; Ogawa K; Nakamura A; Ohira H; Sato Y; Maruyama Y
Leuk Lymphoma; 2006 Jan; 47(1):155-7. PubMed ID: 16321842
[TBL] [Abstract][Full Text] [Related]
10. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Campione E; Diluvio L; Paternò EJ; Di Marcantonio D; Francesconi A; Terrinoni A; Orlandi A; Chimenti S
Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
12. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Drexler HG; MacLeod RA; Uphoff CC
Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report.
Maat Z; Mushtaq K; Yassin MA
Case Rep Oncol; 2021; 14(3):1441-1446. PubMed ID: 34899234
[TBL] [Abstract][Full Text] [Related]
14. Current perspectives for the treatment of chronic myeloid leukemia.
Aladağ E; Haznedaroğlu İC
Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
16. Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
Smith SM; Sabnis HS; Lewis RW; Effinger KE; Bergsagel J; Patterson B; Mertens A; Sakamoto KM; Schapira L; Castellino SM
BMC Cancer; 2021 Apr; 21(1):474. PubMed ID: 33926411
[TBL] [Abstract][Full Text] [Related]
17. Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib.
Junmei Z; Fengkuan Y; Yongping S; Baijun F; Yuzhang L; Lina L; Qinglan Z
Springerplus; 2015; 4():170. PubMed ID: 25897414
[TBL] [Abstract][Full Text] [Related]
18. Targeted drugs in chronic myeloid leukemia.
Gora-Tybor J; Robak T
Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
[TBL] [Abstract][Full Text] [Related]
19. Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Ferreira APS; Seguro FS; Abdo ARN; Santos FM; Maciel FVR; Nardinelli L; Giorgi RR; Ruiz ARL; Ferreira MPS; Rego EM; Rocha V; Bendit I
Ann Hematol; 2023 Jul; 102(7):1761-1771. PubMed ID: 37052662
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.
Lai GM; Yan SL; Chang CS; Tsai CY
World J Gastroenterol; 2013 Feb; 19(8):1318-21. PubMed ID: 23483799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]